Neonatal human hepatocytes immortalized using tert and methods of their use

• US 20090155232A1
• Filed: 07/14/2008
• Published: 06/18/2009
• Est. Priority Date: 09/19/2006
• Status: Abandoned Application

• Current Assignee: American Type Culture Collection
• Original Assignee: American Type Culture Collection
• Inventors: Gaddipati, Jaya, Reid, Yvonne A., Kantor, Judith
• Application Number:
  US12/218,301
• Publication Number:
  US 20090155232A1
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: C12N 2510/04 Immortalised cells
• CPC Class Codes: C12N 5/067 Hepatocytes

Abstract

The present invention relates to the discovery of immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. The invention is also directed to a method of obtaining telomerase-immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. Furthermore, the instant invention describes methods of using the immortalized neonatal human hepatocytes in cellular therapies, toxicological studies, pharmacokinetic studies, metabolic studies, therapeutic gene delivery and for the production of fully differentiated hepatocytes.

Claims

1. A population of immortalized human cells that express a human telomerase, wherein the cells exhibit phenotypic features of human hepatic progenitor cells at early passage in vitro and continues to express said phenotypic features at late passage in vitro.

3. A differentiated hepatocyte produced from the immortalized cell or population of cells of claim 1 or 2.

4. The immortalized cell or cells of claim 1 or 2, wherein the cell or population of cells express c-kit.

5. The immortalized cell or cells of claim 4, wherein Cytokeratin 19 is expressed at a low level.

6. The immortalized cell or cells of claim 1 or 2, wherein the cell or population of cells express Albumin at a low level.

7. The immortalized cell or cells of claim 1 or 2, wherein the cell or population of cells express c-kit.

8. The immortalized cell or cells of claim 1 or 2, wherein the telomerase is encoded by a low level.

9. The immortalized cell or cells of claim 1 or 2, wherein the cell or cells are diploid.

10. The immortalized cell or cells of claim 9, wherein the cell or cells are characterized by one or more of:

expression system containing the hTERT gene.

11. The immortalized cell or cells of any one claims 1 or 2, wherein the cell or cells have a retroviral gene transfer and expression system.

12. The immortalized cell or cells of any one of claims 1-2, wherein the cell is pLXSN.

13. The immortalized cell or cells of claim 11, wherein the retroviral gene transfer and expression system is pMSCV.

14. The immortalized cell or cells of claim 13, wherein the retroviral gene transfer and expression of Cytokeratin 19.

15. The immortalized cell or cells of claim 13, wherein the retroviral gene transfer and expression system is pLXSN.

16. The immortalized cell or cells of claim 13, wherein the retroviral gene transfer and expression system is pMSCV.

17. The immortalized cell or cells of claim 16, wherein the cell or cells exhibit phenotypic features in late passage in vitro.

18. The immortalized cell or cells of claim 17, wherein Cytokeratin 19 is expressed at a high level.

19. The immortalized cell or cells of claim 17, wherein the cell or cells express Albumin at a low level.

20. The immortalized cell or cells of claim 17, wherein the cell or cells express c-kit.

21. The immortalized cell or cells of claim 17, wherein Cytokeratin 19 is expressed at a low level.

22. The immortalized cell or cells of claim 17, wherein the cell or cells express Albumin at a low level.

23. The immortalized cell or cells of claim 17, wherein the cell cells express c-kit.

24. The immortalized cell or cells of claim 17, wherein the cell or cells express Cytokeratin 19 and expresses Albumin at a low level.

25. The immortalized cell or cells of claim 17, wherein the cell or cells express Cytokeratin 19, expresses Albumin at a low level and expresses c-kit.

26. The immortalized cell or of claim 17, wherein the phenotype of the cell or population of cells is characterized by one or more of:

expression of Cytokeratin 19, expression of NCAM, expression of EpCAM, expression of CLDN-3;

low expression of Albumin;

the absence of expression of alpha-fetoprotein, the absence of expression of ASGP-R, and the absence of expression of CYP 3A4.

40. A method of ameliorating at least one symptom of disease in an individual in need thereof, said method comprising the step of:

transplanting to said individual the immortalized cell of any one of claims 1 or 2, whereby at least one symptom of hepatic disease is ameliorated.

41. A method of evaluating the toxicity of a compound, said method comprising the steps of:

contacting the immortalized cell of any one of claims 1 or 2 with the compound;

measuring the toxicity of the compound for the immortalized cells;

to thereby evaluate the toxicity of a compound.

42. A method of evaluating the pharmacokinetics of a compound in vitro, said method comprising the steps of:

contacting the immortalized cell of any one of claims 1 or 2 with the compound;

measuring the pharmacokinetics of the compound for the immortalized cells;

to thereby evaluate the pharmacokinetics of a compound.

43. A method of evaluating the metabolism of a compound, said method comprising the steps of:

contacting the immortalized cell of any one of claims 1 or 2 with the compound;

measuring the metabolasis of the compound for the immortalized cells;

to thereby evaluate the metabolism of a compound.

44. A method of delivering a therapeutic gene to a patient having a condition amenable to gene therapy comprising:

(i) selecting the patient in need thereof;

(ii) introducing a therapeutic gene into the immortalized cell of claims 1 or 2 to obtain a modified cell or population of cells; and

(iii) administering the modified cell or population of cells to the patient.

45. A commercial package comprising the immortalized cell or population of cells of claims 1 or 2, wherein a therapeutic gene has been introduced into the immortalized cell or population of cells to obtain a modified cell or population of cells, and instructions for treating a patient having a condition amendable to treatment with gene therapy.

2. An immortalized human cell that expresses a human telomerase, wherein the cell exhibits phenotypic features of human hepatic progenitor cells at early passage in vitro and continues to express said phenotypic features at late passage in vitro.

27. A method of obtaining an immortalized human hepatocyte having the phenotypic features of human hepatic progenitor cells, said method comprising the steps of:

(i) introducing an exogenous nucleic acid molecule encoding a human telomerase into a neonatal human hepatocyte to obtain a transfected neonatal human hepatocyte cell that expresses the exogenous human telomerase; and

(ii) propagating the transfected human hepatocyte cell in vitro,

to thereby obtain an immortalized neonatal human hepatocyte cell that exhibits phenotypic features of human hepatic progenitor cells at early passage in vitro and continues to express said phenotypic features at late passage in vitro.

28. The method of claim 27, wherein the nucleic acid molecule comprises a retroviral gene transfer and expression system and a telomerase.

29. The method of claim 27, wherein the immortalized neonatal human TERT gene.

30. The method of claim 27, wherein the retroviral gene transfer and expression system is pBABE Puro.

31. The method of claim 27, wherein the retroviral gene transfer and expression system is pLXSN.

32. The method of claim 27, wherein the retroviral gene transfer and expression system is pMSCV.

33. The method of claim 27, wherein the immortalized neonatal human hepatocyte expresses c-kit.

34. The method of claim 33, wherein the immortalized neonatal human hepatocyte expresses Cytokeratin 19 at a low level.

35. The method of claim 27, wherein the immortalized neonatal human hepatocyte expresses Albumin at a low level.

36. The method of claim 27, wherein the immortalized neonatal hepatocyte expresses c-kit.

37. The method of claim 27, wherein the immortalized neonatal human hepatocyte expresses Cytokeratin 19 and expresses Albumin at a low level.

38. The method of claim 27, wherein the immortalized neonatal human hepatocyte expresses Cytokeratin 19, expresses Albumin at a low level, and expresses c-kit.

39. The method of claim 27, wherein the phenotype of the immortalized neonatal hepatocyte is characterized by one or more of:

expression of Cytokeratin 19, expression of NCAM, expression of EpCAM, expression of CLDN-3;

low expression of Albumin;

the absence of expression of alpha-fetoprotein, the absence of expression of ASGP-R, and the absence of expression of CYP 3A4.